1700011I03Rik Activators
700011I03Rik Activators encompass a range of chemical compounds that facilitate the activation of the 1700011I03Rik protein through indirect modulation of various signaling pathways. Forskolin, by increasing intracellular cAMP levels, and Dibutyryl-cAMP, a cAMP analog, both activate protein kinase A (PKA), which may phosphorylate and enhance the activity of 1700011I03Rik if it is under PKA regulation. Similarly, IBMX's inhibition of phosphodiesterases leads to raised levels of cAMP and cGMP, potentially intensifying PKA or PKG pathway activity and thus the activity of 1700011I03Rik. The PKC activator PMA could also play a role if 1700011I03Rik is a substrate of PKC-mediated signaling. Calcium modulators like Ionomycin and Thapsigargin, which increase intracellular calcium, could activate calcium-dependent kinases, thus influencing 1700011I03Rik's state if it is responsive to calcium signaling. Sildenafil, by elevating cGMP levels, could similarly enhance 1700011I03Rik activity through PKG activation.
Furthermore, LY294002's inhibition of PI3K and PD98059's blockade of MEK could lead to alterations in AKT and MAPK/ERK signaling, respectively, which may have downstream effects on the functional state of 1700011I03Rik. Epigallocatechin gallate, which inhibits several protein kinases, could relieve negative regulatory effects on 1700011I03Rik, thereby enhancing its activity. SB203580's specific inhibition of p38 MAP kinase might redirect signaling to favor pathways that activate 1700011I03Rik, if it is involved in stress-response pathways. These compounds, through their specific actions on cellular signaling pathways, collectively contribute to the indirect enhancement of 1700011I03Rik activity by modulating the protein's regulatory environment without directly influencing its expression levels or requiring direct binding interactions to exert their effects.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which degrade cAMP and cGMP. By preventing this degradation, IBMX can indirectly increase PKA activity, which may enhance the phosphorylation and activity of 1700011I03Rik if it is PKA-regulated. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) is an activator of protein kinase C (PKC). If 1700011I03Rik is a substrate or is regulated by PKC, PMA could indirectly increase its activity through PKC-mediated signaling pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, possibly activating calcium-dependent protein kinases, which could enhance the activity of 1700011I03Rik if it is sensitive to calcium-dependent phosphorylation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate (EGCG) can inhibit several protein kinases. If 1700011I03Rik is negatively regulated by one of these kinases, EGCG could lead to an increase in 1700011I03Rik activity by inhibiting its negative regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K. Inhibition of PI3K can alter AKT signaling pathways. If 1700011I03Rik is part of a signaling cascade downstream of AKT, LY294002 may indirectly enhance the activity of 1700011I03Rik by modifying AKT-related signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. If the activity of 1700011I03Rik is enhanced by signaling through ERK, inhibition of its upstream kinase MEK could result in altered signaling dynamics that indirectly activate 1700011I03Rik. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor, leading to increased cytosolic calcium levels. If 1700011I03Rik is activated by calcium signaling, thapsigargin could enhance its activity by elevating intracellular calcium. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cell-permeable cAMP analog that activates PKA. If 1700011I03Rik activity is modulated through PKA, this compound could indirectly enhance 1700011I03Rik activity by mimicking cAMP's role in PKA activation. | ||||||